Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 DiabetesBusiness Wire • 07/05/22
Strength Seen in Vertex (VRTX): Can Its 4.8% Jump Turn into More Strength?Zacks Investment Research • 06/20/22
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani on Goldman Sachs 43rd Annual Healthcare Conference (Transcript)Seeking Alpha • 06/15/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the FirmNewsfile Corp • 06/14/22
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) CongressBusiness Wire • 06/11/22
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis ConferenceBusiness Wire • 06/10/22
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15Business Wire • 06/08/22